A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

March 08, 2023
PACIFIC-8
Lung Cancer
Rand Naffouje, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

Sponsor: AstraZeneca

https://clinicaltrials.gov/ct2/show/NCT05211895

  • Previously treated with chemotherapy and radiation therapy at the same time for locally advanced, unresectable (Stage III) disease
  • Must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy and not progressed during or after.
  • No other primary malignancy (with some exceptions) unless treated and there has been no active disease for at least 5 years. before the first dose of study intervention and of low potential risk for recurrence. 
  • No mixed small cell and non-small cell lung cancer.

Approx. 6 years

Accepting Participants
Interventional
III
Jessica Schnase, Mgr Cancer Research
630-646-6072
630-646-6074
630-646-6073